RNA interference (RNAi) has rapidly become a powerful tool for target discovery and therapeutics. Small interfering RNAs (siRNAs) are highly effective in mediating sequence-specific gene silencing. However, the major obstacle for using siRNAs as cancer therapeutics is their systemic delivery from the administration site to target cells in vivo. This chapter describes approaches to deliver siRNA effectively for cancer treatment and discusses in detail the current methods to assess pharmacokinetics and biodistribution of siRNAs in vivo.
CITATION STYLE
Hatakeyama, H., Wu, S. Y., Mangala, L. S., Lopez-Berestein, G., & Sood, A. K. (2016). Assessment of In vivo siRNA delivery in cancer mouse models. In Methods in Molecular Biology (Vol. 1402, pp. 189–197). Humana Press Inc. https://doi.org/10.1007/978-1-4939-3378-5_15
Mendeley helps you to discover research relevant for your work.